Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose oral ceftibuten safety and pharmacokinetics study in healthy volunteers
NL-OMON49030Completed
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in bacterial disease and Gram-negative bacterial infection comparing Ceftibuten with Placebo (2 arms). Primary endpoint: Safety of increasing doses of oral ceftibuten. Started Jul 2020; status: completed.
02
Drugs
ceftibuten
03
Conditions
bacterial diseaseGram-negative bacterial infection
Beyond the preview
Go deeper on NL-OMON49030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49030.